SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability

Atorvastatin, prescribed for the treatment of hypercholesterolemia, demonstrated overwhelming benefits in reducing cardiovascular morbidity and mortality. However, many patients discontinue therapy due to adverse reactions, especially myopathy. The Dutch Pharmacogenetics Working Group (DPWG) recomme...

Descripción completa

Detalles Bibliográficos
Autores principales: Zubiaur, Pablo, Benedicto, Maria Dolores, Villapalos-García, Gonzalo, Navares-Gómez, Marcos, Mejía-Abril, Gina, Román, Manuel, Martín-Vílchez, Samuel, Ochoa, Dolores, Abad-Santos, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999651/
https://www.ncbi.nlm.nih.gov/pubmed/33805706
http://dx.doi.org/10.3390/jpm11030204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999651/
https://www.ncbi.nlm.nih.gov/pubmed/33805706
http://dx.doi.org/10.3390/jpm11030204

Ejemplares similares